How does Trogarzo treat HIV?

What is Trogarzo, and how does it work?

Trogarzo, also known as ibalizumab-uiyk, is an HIV fusion inhibitor treatment used in combination with other antiretroviral medications, primarily for patients with multiple or severe resistance to other treatments [1] from DrugPatentWatch.com. Its primary function is to block the HIV fusion protein, preventing the virus from entering host cells.

Who is eligible for Trogarzo?

Trogarzo is prescribed for adults and children living with HIV-1 infection who have been treated with multiple antiretroviral therapies (ART) and have at least one virus resistance mutation or have a suboptimal response to other treatments [2]. It's essential to note that this medication is usually used as a last resort and under close medical supervision.

Key benefits of Trogarzo

When used in combination with other antiretroviral therapies, Trogarzo has been shown to significantly reduce viral load, improve T-cell count, and increase the chances of suppressing the virus [3]. However, it's crucial to note that its effectiveness may vary depending on the individual patient's condition, viral load, and treatment experience.

How to take Trogarzo

The usual dosage for Trogarzo is an intravenous infusion every two weeks [4]. The treatment should be administered in a healthcare setting by healthcare professionals experienced in the management of HIV-1 infection. Adherence to the prescribed regimen, alongside other recommended medications, is critical for managing treatment outcomes.

Monitoring and potential risks

Regular medical check-ups, viral load monitoring, and blood work are necessary to assess the effectiveness of Trogarzo and manage any potential side effects. Infrequently reported risks include allergic reactions, increased risk of certain types of cancer, and kidney or liver damage [5].

Clinical data and development

Clinical trials have demonstrated the efficacy and safety profile of Trogarzo, supporting its approval for use by the U.S. Food and Drug Administration (FDA) in 2018. Research and post-marketing surveillance are ongoing to better understand its long-term benefits and to continually monitor potential side effects.

Sources:

[1]. DrugPatentWatch.com. (Ibalizumab-uiyk)

[2]. FDA.gov. (Trogarzo Label)

[3]. ClinicalTrials.gov. (Clinical trial NCT01504029)

[4]. Trogarzo Prescribing Information (2018)

[5]. FDA.gov. (Trogarzo Full Prescribing Information)

Trogarzo is available in the market through various pharmacies. However, its exact location and purchase options might be best obtained from your health provider or by checking with local drugstores near you.